Åermin GenÃ§

List of Publications by Year
in descending order

88 papers	4,941 citations	109321 35 h-index	95266 68 g-index
90 all docs	90 docs citations	90 times ranked	7186 citing authors

#	Article	IF	Citations
1	MicroRNAs in Genetic Etiology of Human Diseases. Methods in Molecular Biology, 2022, 2257, 255-268.	0.9	5
2	Role of Exosomal MicroRNAs in Cell-to-Cell Communication. Methods in Molecular Biology, 2022, 2257, 269-292.	0.9	5
3	Targeting NLRP3 Inflammasome With Nrf2 Inducers in Central Nervous System Disorders. Frontiers in Immunology, 2022, 13, 865772.	4.8	26
4	Alteration of miRNAs in Small Neuron-Derived Extracellular Vesicles of Alzheimer's Disease Patients and the Effect of Extracellular Vesicles on Microglial Immune Responses. Journal of Molecular Neuroscience, 2022, 72, 1182-1194.	2.3	12
5	Melatonin Alters the miRNA Transcriptome of Inflammasome Activation in Murine Microglial Cells. Neurochemical Research, 2022, 47, 3202-3211.	3.3	2
6	Endothelial Protein C Receptor Expression is Regulated by Sp1 Transcription Factor in Murine Microglia. Journal of Basic and Clinical Health Sciences, 2021, 5, 6-13.	0.4	0
7	Ethyl Pyruvate Attenuates Microglial NLRP3 Inflammasome Activation via Inhibition of HMGB1/NF-ÎºB/miR-223 Signaling. Antioxidants, 2021, 10, 745.	5.1	10
8	Lithium inhibits oxidative stress-induced neuronal senescence through miR-34a. Molecular Biology Reports, 2021, 48, 4171-4180.	2.3	9
9	Sulforaphane inhibits NLRP3 inflammasome activation in microglia through Nrf2-mediated miRNA alteration. Immunology Letters, 2021, 233, 20-30.	2.5	23
10	Proteome profiling of neuron-derived exosomes in Alzheimer's disease reveals hemoglobin as a potential biomarker. Neuroscience Letters, 2021, 755, 135914.	2.1	23
11	The Role of Melatonin on NLRP3 Inflammasome Activation in Diseases. Antioxidants, 2021, 10, 1020.	5.1	25
12	Inhibitory effects of sulforaphane on NLRP3 inflammasome activation. Molecular Immunology, 2021, 140, 175-185.	2.2	20
13	Resveratrol Inhibits NLRP3 Inflammasome-Induced Pyroptosis and miR-155 Expression in Microglia Through Sirt1/AMPK Pathway. Neurotoxicity Research, 2021, 39, 1812-1829.	2.7	28
14	Dimethyl Fumarate Alleviates NLRP3 Inflammasome Activation in Microglia and Sickness Behavior in LPS-Challenged Mice. Frontiers in Immunology, 2021, 12, 737065.	4.8	39
15	Circulating exosomal microRNAs in bipolar disorder. Journal of Affective Disorders, 2020, 262, 99-107.	4.1	49
16	Microglial NLRP3 inflammasome activation in multiple sclerosis. Advances in Protein Chemistry and Structural Biology, 2020, 119, 247-308.	2.3	48
17	Oxygen exposure in early life activates NLRP3 inflammasome in mouse brain. Neuroscience Letters, 2020, 738, 135389.	2.1	7
18	Inhibitory effects of phytochemicals on NLRP3 inflammasome activation: A review. Phytomedicine, 2020, 75, 153238.	5.3	28

#	Article	IF	Citations
19	Melatonin Attenuates LPS-Induced Acute Depressive-Like Behaviors and Microglial NLRP3 Inflammasome Activation Through the SIRT1/Nrf2 Pathway. Frontiers in Immunology, 2019, 10, 1511.	4.8	299
20	Examination of IL-1Î² level as an inflammasome marker in Alzheimer's disease. Neurological Sciences and Neurophysiology, 2019, 36, 141-147.	0.3	0
21	Stem Cell Therapy for Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2018, 1084, 145-174.	1.6	44
22	Sulforaphane Inhibits Lipopolysaccharide-Induced Inflammation, Cytotoxicity, Oxidative Stress, and miR-155 Expression and Switches to Mox Phenotype through Activating Extracellular Signal-Regulated Kinase 1/2â€"Nuclear Factor Erythroid 2-Related Factor 2/Antioxidant Response Element Pathway in Murine Microglial Cells. Frontiers in Immunology, 2018, 9, 36.	4.8	54
23	Follow-up Analysis of Serum TNF-Related Apoptosis-Inducing Ligand Protein and mRNA Expression in Peripheral Blood Mononuclear Cells from Patients with Ischemic Stroke. Frontiers in Neurology, 2018, 9, 102.	2.4	8
24	Peptide Derivatives of Erythropoietin in the Treatment of Neuroinflammation and Neurodegeneration. Advances in Protein Chemistry and Structural Biology, 2018, 112, 309-357.	2.3	9
25	Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: Past, present, and future. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 73, 87-103.	4.8	72
26	Stem Cell-Based Approaches for Treatment of Glioblastoma. Stem Cells in Clinical Applications, 2017, , 65-82.	0.4	0
27	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimerâ€™s Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	2.6	10
28	Proteomic analysis of erythropoietin-induced changes in neuron-like SH-SY5Y cells. Turkish Journal of Biochemistry, 2017, 42, 213-221.	0.5	0
29	MicroRNA exocytosis by large dense-core vesicle fusion. Scientific Reports, 2017, 7, 45661.	3.3	19
30	Induced Pluripotent Stem Cell Therapy and Safety Concerns in Age-Related Chronic Neurodegenerative Diseases. Stem Cells in Clinical Applications, 2017, , 23-65.	0.4	0
31	A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. Brain, 2017, 140, 1128-1146.	7.6	84
32	Erythropoietin Promotes Glioblastoma via miR-451 Suppression. Vitamins and Hormones, 2017, 105, 249-271.	1.7	14
33	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-Î² Levels inÂPatients with Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2015, 47, 1069-1078.	2.6	28
34	Lithium protects against paraquat neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells. Frontiers in Cellular Neuroscience, 2015, 9, 209.	3.7	58
35	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	2.4	348
36	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	3.1	30

#	Article	IF	Citations
37	Expression Patterns of Micro-RNAs 146a, 181a, and 155 in Subacute Sclerosing Panencephalitis. Journal of Child Neurology, 2015, 30, 69-74.	1.4	6
38	EPO Mediates Neurotrophic, Neuroprotective, Anti-Oxidant, and Anti-Apoptotic Effects via Downregulation of miR-451 and miR-885-5p in SH-SY5Y Neuron-Like Cells. Frontiers in Immunology, 2014, 5, 475.	4.8	46
39	The Role of MicroRNAs in Human Diseases. Methods in Molecular Biology, 2014, 1107, 33-50.	0.9	189
40	The Role of MicroRNAs in Biological Processes. Methods in Molecular Biology, 2014, 1107, 15-31.	0.9	142
41	Neurodegenerative Disease Phenotypes in Carriers of MAPT p.A152T, A Risk Factor for Frontotemporal Dementia Spectrum Disorders and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2013, 27, 302-309.	1.3	40
42	Inflammation in Parkinson's Disease. Advances in Protein Chemistry and Structural Biology, 2012, 88, 69-132.	2.3	154
43	The Adverse Effects of Air Pollution on the Nervous System. Journal of Toxicology, 2012, 2012, 1-23.	3.0	438
44	Resveratrol Reduces Matrix Metalloproteinase-2 Activity Induced by Oxygen-Glucose Deprivation and Reoxygenation in Human Cerebral Microvascular Endothelial Cells. International Journal for Vitamin and Nutrition Research, 2012, 82, 267-274.	1.5	9
45	Patient-Specific Pluripotent Stem Cells in Neurological Diseases. Stem Cells International, 2011, 2011, 1-17.	2.5	34
46	The Endotoxin-Induced Neuroinflammation Model of Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-25.	1.1	70
47	Erythropoietin in neonatal brain protection: The past, the present and the future. Brain and Development, 2011, 33, 632-643.	1.1	54
48	Intranasal erythropoietin therapy in nervous system disorders. Expert Opinion on Drug Delivery, 2011, 8, 19-32.	5.0	19
49	MicroRNAs and Multiple Sclerosis. Autoimmune Diseases, 2011, 2011, 1-27.	0.6	53
50	The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-14.	1.1	120
51	Erythropoietin induces nuclear translocation of Nrf2 and heme oxygenaseâ€1 expression in SHâ€SY5Y cells. Cell Biochemistry and Function, 2010, 28, 197-201.	2.9	41
52	Protective Effects of Methylxanthines on Hypoxia-Induced Apoptotic Neurodegeneration and Long-Term Cognitive Functions in the Developing Rat Brain. Neonatology, 2010, 98, 128-136.	2.0	18
53	Safety Concerns With the Clinical Use of Erythropoietin in Acute Ischemic Stroke. Stroke, 2010, 41, e469.	2.0	2
54	White Matter Protection by Erythropoietin: An Emerging Matter in the Treatment of Neonatal Hypoxicâ€"Ischemic Brain Injury. Stroke, 2010, 41, e595; author reply e596.	2.0	6

#	Article	IF	Citations
55	Protective Effects of Topiramate against Hyperoxic Brain Injury in the Developing Brain. Neuropediatrics, 2009, 40, 22-27.	0.6	15
56	Pregnenolone protects the PC-12 cell line against amyloid beta peptide toxicity but its sulfate ester does not. Chemico-Biological Interactions, 2009, 177, 65-70.	4.0	16
57	Biological markers in cerebrospinal fluid (CSF) and evaluation of <i>in vitro</i> effect of CSF on PC12 cell line viability in Alzheimer's disease. Cell Biochemistry and Function, 2009, 27, 395-401.	2.9	2
58	TNF-related apoptosis-inducing ligand level in Alzheimerâ€™s disease. Neurological Sciences, 2009, 30, 263-267.	1.9	19
59	Oxidative stress and dysregulated Nrf2 activation in the pathogenesis of schizophrenia. Bioscience Hypotheses, 2009, 2, 16-18.	0.2	11
60	Oxidative DNA damage in polymorphonuclear leukocytes of patients with familial Mediterranean fever. Free Radical Biology and Medicine, 2008, 44, 386-393.	2.9	45
61	Hyperoxic exposure leads to cell death in the developing brain. Brain and Development, 2008, 30, 556-562.	1.1	67
62	Erythropoietin and Parkinsonâ€™s disease: Suggested mechanisms and therapeutic implications. Medical Hypotheses, 2008, 70, 211-212.	1.5	3
63	Effect of erythropoietin on oxygen-induced brain injury in the newborn rat. Neuroscience Letters, 2008, 448, 245-249.	2.1	37
64	Erythropoietin Attenuates Lipopolysaccharide-Induced White Matter Injury in the Neonatal Rat Brain. Neonatology, 2007, 92, 269-278.	2.0	88
65	99mTc-HMPAO labelling inhibits cell motility and cell proliferation and induces apoptosis of NCâ€“NC cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2007, 631, 69-76.	1.7	5
66	Activated protein C reduces endotoxin-induced white matter injury in the developing rat brain. Brain Research, 2007, 1164, 14-23.	2.2	25
67	Endothelial nitric oxide-mediated Nrf2 activation as a novel mechanism for vascular and neuroprotection by erythropoietin in experimental subarachnoid hemorrhage. Medical Hypotheses, 2006, 67, 424.	1.5	5
68	Neuroprotective effect of the peptides ADNF-9 and NAP on hypoxicâ€“ischemic brain injury in neonatal rats. Brain Research, 2006, 1115, 169-178.	2.2	33
69	Erythropoietin Downregulates Bax and DP5 ProApoptotic Gene Expression in Neonatal Hypoxic-Ischemic Brain Injury. Neonatology, 2006, 89, 205-210.	2.0	57
70	Erythropoietin Signaling and Neuroprotection. Current Signal Transduction Therapy, 2006, 1, 209-218.	0.5	0
71	Protective effects of erythropoietin against ethanol-induced apoptotic neurodegenaration and oxidative stress in the developing C57BL/6 mouse brain. Developmental Brain Research, 2005, 160, 146-156.	1.7	58
72	Does Antioxidant Supplementation Alter the Effects of Acute Exercise on Erythrocyte Aggregation, Deformability and Endothelium Adhesion in Untrained Rats?. International Journal for Vitamin and Nutrition Research, 2005, 75, 243-250.	1.5	5

#	ARTICLE	IF	CITATIONS
73	Hyperbilirubinemic Serum Is Cytotoxic and Induces Apoptosis in Murine Astrocytes. Neonatology, 2005, 87, 99-104.	2.0	18
74	Erythropoietin Increases Glutathione Peroxidase Enzyme Activity and Decreases Lipid Peroxidation Levels in Hypoxic-Ischemic Brain Injury in Neonatal Rats. Neonatology, 2005, 87, 15-18.	2.0	103
75	Selective Inhibition of Nitric Oxide in Hypoxic-Ischemic Brain Model in Newborn Rats: Is It an Explanation for the Protective Role of Erythropoietin?. Neonatology, 2004, 85, 51-54.	2.0	73
76	Erythropoietin and the nervous system. Brain Research, 2004, 1000, 19-31.	2.2	152
77	Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxiaâ€“ischemia in rats. Behavioural Brain Research, 2004, 153, 77-86.	2.2	173
78	RNA interference in neuroscience. Molecular Brain Research, 2004, 132, 260-270.	2.3	16
79	Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxicâ€“ischemic brain injury. Brain and Development, 2003, 25, 494-498.	1.1	85
80	Methamphetamine induces oligodendroglial cell death in vitro. Brain Research, 2003, 982, 125-130.	2.2	25
81	Bilirubin is cytotoxic to rat oligodendrocytes in vitro. Brain Research, 2003, 985, 135-141.	2.2	39
82	Interferon gamma and lipopolysaccharide upregulate TNF-related apoptosis-inducing ligand expression in murine microglia. Immunology Letters, 2003, 85, 271-274.	2.5	21
83	Neuroprotective Effect of Erythropoietin on Hypoxic-Ischemic Brain Injury in Neonatal Rats. Neonatology, 2003, 83, 224-228.	2.4	140
84	Erythropoietin Protects against Necrotizing Enterocolitis of Newborn Rats by the Inhibiting Nitric Oxide Formation. Neonatology, 2003, 84, 325-329.	2.0	30
85	Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2258-2263.	7.1	435
86	Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neuroscience Letters, 2002, 321, 73-76.	2.1	124
87	Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neuroscience Letters, 2001, 298, 139-141.	2.1	122
88	A Case of Lafora's Disease Associated With Cardiac Arrhythmia. Journal of Child Neurology, 1999, 14, 745-746.	1.4	14